Bharat Biotech asked to submit complete phase 2 data of its COVID-19 vaccine before phase 3 trial

Bharat Biotech asked to submit complete phase 2 data of its COVID-19 vaccine before phase 3 trial
NEW DELHI: Bharat Biotech, which had sought DCGI’s nod for conducting phase-3 clinical trials of its COVID-19 vaccine candidate, has been asked to submit complete safety and immunogenicity data of the continued phase-2 trial, besides providing some clarifications, before proceeding for subsequent stage.
The vaccine candidate — ‘Covaxin’ — is being indigenously developed by the Bharat Biotech together with the Indian Council of Medical Research (ICMR).
According to officials, the Hyderabad-based vaccine maker applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission to conduct phase-3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine candidate.
The firm in its application said that the study would cover 28,500 subjects aged 18 years and above and would be conducted in 19 sites — including Delhi, Mumbai, Patna and Lucknow — across 10 states.
According to sources, the phase-2 trial of the Covaxin goes on and therefore the second dose is yet to tend to volunteers at some sites.
“The company presented phase-3 clinical test protocol along side interim data of phase 1 and a couple of clinical trials,” a politician said.
The subject expert committee (SEC) at the Central Drugs Standard Control Organisation(CDSCO) deliberated on the appliance on October 5.
“After an in depth deliberation, the committee opined that the planning of the phase-3 study is in theory satisfactory apart from clarification on definition of asymptomatic, etc.
“However, the study should be initiated with appropriate dose identified from the phase-2 safety and immunogenicity data. Accordingly, the firm should submit safety and immunogenicity data from phase-2 trial for consideration,” the panel said in its recommendations.
The SEC during its discussion also observed that the vaccine was well-tolerated altogether dose groups and no serious adverse events are reported thus far , a source said.
The most common adverse event was pain at the injection site, which resolved transiently, the source said.
The phase-3 clinical test application proposed a dose of 0.5 ml on day 0 and 28, sources said.
Besides, Bharat Biotech, indigenously developed vaccine candidate by Zydus Cadila Ltd is within the phase 2 of the human clinical trials.
The Pune-based Serum Institute of India, which has partnered with AstraZeneca for manufacturing the Oxford COVID-19 vaccine candidate, is additionally conducting Phase 2 and three human clinical trials of the candidate in India.

Advertisement

author

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *